Table 4. Adverse events of special interest to chemotherapy and key events pooled by body system (treatment-related and unrelated).

	FOLFOX4-bevacizumab (n=342)				XELOX-bevacizumab (n=353)
	All-grade		Grade 3/4		All-grade		Grade 3/4
	No.	%	No.	%	No.	%	No.	%
All events	340	99	289	85	351	99	266	75
Body system
Gastrointestinal disorders	320	94	94	28	325	92	132	37
Blood/lymphatic disorders	229	67	159	47	125	35	44	13
Infections/infestations	164	42	31	9	137	39	21	6
Events of special interest
Neurosensory toxicitya	281	82	61	18	296	84	64	18
Diarrhoea	219	64	44	13	224	64	77	22
Nausea/vomiting	235	69	25	7	252	71	38	11
Stomatitis	141	41	12	4	102	29	7	2
Neutropenia/granulocytopenia	189	55	138	40	70	20	25	7
Febrile neutropenia	—	—	15	4	—	—	4	1
Hand-foot syndrome	47	14	6b	2b	141	40	42b	12b

Abbreviations: FOLFOX4=infused 5-fluorouracil, folinic acid and oxaliplatin; XELOX=capecitabine and oxaliplatin.

^aPooled term that includes burning sensation, dysaesthesia, hyper or hypoaesthesia, neuropathic pain, neuropathy, peripheral neuropathy, neurotoxicity, paraesthesia, peripheral (sensi)motor neuropathy, (chronic) polyneuropathy, sensory disturbance or loss, skin burning sensation, temperature intolerance, neuralgia, peroneal nerve palsy, autonomic neuropathy.

^bGrade 3 events only.